Plasma mcfDNA sequencing for predicting and diagnosing bloodstream infection in high-risk leukaemia (Wolf et al. 2026)
Episode-level sensitivity against blood-culture organisms before and at bloodstream infection onset, and specificity in afebrile control samples.
Results are recorded on the linked protocols, tasks or configurations listed below. Their settings and evaluations are kept separate.
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
Results on linked records
This benchmark has no results of its own in this release. 3 linked records have results. They are not assigned to the underlying benchmark: each record keeps its own settings and evaluations, and its scores are on its own page.
- Diagnostic sensitivity, day 0 or 1 (Wolf et al. 2026 Table 2) Protocol · part of this benchmark · 1 evaluation · 18 results
- Predictive sensitivity, day -3 to -1 (Wolf et al. 2026 Table 2) Protocol · part of this benchmark · 1 evaluation · 18 results
- Predictive specificity in control samples (Wolf et al. 2026 Table 3) Protocol · part of this benchmark · 2 evaluations · 8 results
Methods and evaluation design
Procedure, tasks and evaluated configurations
Baseline coverage
Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.
0 of 6 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.
Baseline status by linked protocol
- Diagnostic sensitivity, day 0 or 1 (Wolf et al. 2026 Table 2) · 0/2 roles measured
- Predictive sensitivity, day -3 to -1 (Wolf et al. 2026 Table 2) · 0/2 roles measured
- Predictive specificity in control samples (Wolf et al. 2026 Table 3) · 0/2 roles measured
Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)
Coverage is derived from release 2026-10-22-1b7cf027e4f6. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.
Run instructions
No runnable recipe has been reviewed for this benchmark. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.
Strengths, limitations and unresolved questions
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
0 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|
No evidence rows match these filters. Choose another scope or clear the search.
Sources and history
Release 2026-10-22-1b7cf027e4f6 · Record review: source checked
1 source record and release history
- Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study · Original source · The Lancet Microbe 7:101312, published online 2026-03-02; PMC13154368 full-text XML (author manuscript)
Technical metadata and extraction receipts
Stable ID: dna-pathogen-20261011-wolf2026-benchmark-mcfdna-bsi
- areas
- microbes-communities
- contexts
- clinical_research
- entity level
- suite
- version
- Lancet Microbe 2026, Tables 2 and 3
- task
- Detect the blood-culture organism in plasma cell-free DNA before and at bloodstream infection onset
- source locator
- Methods 'Outcomes' and 'Statistical analysis'
- scope note
- Day-by-day sensitivity (Figure 2 and appendix) and the appendix tables were not extracted.
- limitations
- One commercial assay; no comparator workflow.